In the phase 3 AURA3 study, osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced NSCLC in whom disease had progressed during first-line EGFR-TKI therapy [9]. Here, EGFR is linked to non-small cell lung carcinoma.